1. Home
  2. AVTX vs HLVX Comparison

AVTX vs HLVX Comparison

Compare AVTX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVTX
  • HLVX
  • Stock Information
  • Founded
  • AVTX 2011
  • HLVX 2020
  • Country
  • AVTX United States
  • HLVX United States
  • Employees
  • AVTX N/A
  • HLVX N/A
  • Industry
  • AVTX Biotechnology: Pharmaceutical Preparations
  • HLVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVTX Health Care
  • HLVX Health Care
  • Exchange
  • AVTX Nasdaq
  • HLVX Nasdaq
  • Market Cap
  • AVTX 57.4M
  • HLVX 83.7M
  • IPO Year
  • AVTX 2015
  • HLVX 2022
  • Fundamental
  • Price
  • AVTX $4.89
  • HLVX $2.09
  • Analyst Decision
  • AVTX Strong Buy
  • HLVX Hold
  • Analyst Count
  • AVTX 7
  • HLVX 5
  • Target Price
  • AVTX $31.00
  • HLVX $2.33
  • AVG Volume (30 Days)
  • AVTX 82.2K
  • HLVX 430.4K
  • Earning Date
  • AVTX 08-11-2025
  • HLVX 08-07-2025
  • Dividend Yield
  • AVTX N/A
  • HLVX N/A
  • EPS Growth
  • AVTX N/A
  • HLVX N/A
  • EPS
  • AVTX N/A
  • HLVX N/A
  • Revenue
  • AVTX $441,000.00
  • HLVX N/A
  • Revenue This Year
  • AVTX N/A
  • HLVX N/A
  • Revenue Next Year
  • AVTX N/A
  • HLVX N/A
  • P/E Ratio
  • AVTX N/A
  • HLVX N/A
  • Revenue Growth
  • AVTX N/A
  • HLVX N/A
  • 52 Week Low
  • AVTX $3.39
  • HLVX $1.34
  • 52 Week High
  • AVTX $16.00
  • HLVX $2.15
  • Technical
  • Relative Strength Index (RSI)
  • AVTX 54.89
  • HLVX 63.08
  • Support Level
  • AVTX $4.63
  • HLVX $1.98
  • Resistance Level
  • AVTX $5.02
  • HLVX $2.12
  • Average True Range (ATR)
  • AVTX 0.27
  • HLVX 0.08
  • MACD
  • AVTX 0.00
  • HLVX 0.01
  • Stochastic Oscillator
  • AVTX 72.73
  • HLVX 89.66

About AVTX Avalo Therapeutics Inc.

Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

About HLVX HilleVax Inc.

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Share on Social Networks: